Mariani Stefania, Basciani Sabrina, Giona Fiorina, Lubrano Carla, Ulisse Salvatore, Gnessi Lucio
Department of Experimental Medicine, Sapienza University of Rome, Italy.
Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Italy.
Leuk Res Rep. 2013 Aug 8;2(2):58-60. doi: 10.1016/j.lrr.2013.07.001. eCollection 2013.
We evaluated serum leptin levels in 9 young chronic myeloid leukemia (CML) patients under imatinib therapy during a long-term follow-up. Body mass index (BMI) and fat mass percentage (%FM) were also measured. Leptin was above the normal range in 8 out of 9 patients. In one case the hormone was below the reference value. All subjects showed a normal BMI, but 3 had a small increase of FM%. One patient recovered the leptin normal value after imatinib suspension. A tendency to leptin normalization in patients switched to an intermittent therapy was also found. This study suggests that imatinib therapy may result in leptin alteration.
我们在长期随访期间评估了9例接受伊马替尼治疗的年轻慢性髓性白血病（CML）患者的血清瘦素水平。还测量了体重指数（BMI）和脂肪量百分比（%FM）。9例患者中有8例的瘦素高于正常范围。1例患者的该激素低于参考值。所有受试者的BMI均正常，但3例患者的FM%略有增加。1例患者在停用伊马替尼后瘦素恢复到正常值。在改用间歇疗法的患者中也发现了瘦素趋于正常化的趋势。本研究表明，伊马替尼治疗可能导致瘦素改变。
